Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Ferrara – page 7

196 clinical trials in Ferrara, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Ferrara at a glance
196
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

196 trials in Ferrara

Open in trial search

Acute lymphocytic leukaemia

Recruiting

Study of Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Chronic lymphocytic leukaemia

Recruiting

Study of venetoclax, obinutuzumab and zanubrutinib combination therapy in young patients with high-risk Chronic Lymphocytic Leukemia and residual disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Allopurinol
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Hormone-dependent prostate cancer+1

Recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Novartis Pharma AG

Chronic lymphocytic leukaemia+1

Recruiting

Study on Ibrutinib and Venetoclax for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Janssen Cilag International

Systemic lupus erythematosus

Recruiting

Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Acute myeloid leukaemia

Recruiting

Study on Early Treatment Intensification for Acute Myeloid Leukemia with FLT3 Mutation Using Cytarabine, Midostaurin, and Daunorubicin Hydrochloride for Patients with Low Chemosensitivity

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Malignant melanoma

Recruiting

Study to Compare Fianlimab and Cemiplimab Combination with Pembrolizumab in Patients with High-Risk Melanoma After Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Chronic obstructive pulmonary disease

Not yet recruiting

Study of Two Doses of EXPD-101 vs Placebo for Reducing COPD Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Asthma

Not yet recruiting

Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Chiesi Farmaceutici S.p.A.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Ferrara

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on heart failure prevention and treatment of cardiovascular conditions, including trials testing new therapies for high-risk patients.

  • Heart Failure Prevention
  • Cardiovascular Disease Management
  • Myocardial Infarction Research

Advanced clinical investigations exploring precision medicine approaches and preventive interventions.

02 Oncology Studies

Comprehensive research into various cancer types, including pleural mesothelioma and breast cancer, evaluating novel treatment combinations and therapeutic approaches.

  • Leukemia Treatments
  • Breast Cancer Therapy
  • Lymphoma Management

Focus on improving patient outcomes through targeted therapies and immunotherapy protocols.

03 Immunological Disorders

Studies examining treatments for psoriatic arthritis and other autoimmune conditions, investigating innovative biological therapies.

  • Autoimmune Disease Treatment
  • Respiratory Conditions
  • Inflammatory Disorders

Investigation of novel therapeutic approaches for chronic inflammatory conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.